1. Inicio
  2. Publicaciones
  3. Daclizumab in multiple sclerosis.

Daclizumab in multiple sclerosis.

Fecha de publicación:

Autores de IIS La Fe

Abstract

Daclizumab is a monoclonal antibody directed against the CD25 subunit of the interleukin-2 receptor, investigated as a disease-modifying therapy in relapsing-remitting multiple sclerosis. The present review addresses how the drug was developed, the known mechanism of action of the drug and the up-to-date data of efficacy and safety.

Datos de la publicación

ISSN/ISSNe:
0210-0010, 1576-6578

REVISTA DE NEUROLOGIA  REVISTA DE NEUROLOGIA

Tipo:
Review
Páginas:
271-282
PubMed:
29645071
Factor de Impacto:
0,199 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 6

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Daclizumab; Interleukine 2; Monoclonal antibody; Multiple sclerosis; NK cell; Safety

Campos de Estudio

Cita

Compartir